-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia |Diana Isaacs
CommentaryVideoJune 20, 2025Author(s):,Expert shares key upcoming sessions at the American Diabetes Association 85th Scientific Sessions. In an interview with Pharmacy Times®, Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, remote monitoring program coordinator and endocrinology clinical pharmacy specialist at the Cleveland Clinic, shares insights about the upcoming American Diabetes Association 85th Scientific Sessions.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
Author(s):Fact checked by:New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies. Respiratory syncytial virus (RSV) in adults signifies a significant and underestimated public health burden due to challenges of underdiagnosis, stemming from nonspecific symptoms and limitations in testing.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
Physical exercise in combination with omega-3 supplementation was reported to improve the immune response and reduce the severity of chronic apical periodontitis, according to findings published by investigators in the journal Scientific Reports.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
Emerging study findings from investigators at Linköping University discovered that 6 out of 10 individuals with type 2 diabetes (T2D) had fatty liver.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
The FDA approved garadacimab-gxii (Andembry; CSL) for targeting Xlla for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients ages 12 years and older.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
Eli Lilly and Company announced that the highest approved doses of tirzepatide (Zepbound), 12.5 mg and 15 mg, will soon be offered in single-dose vials for $499 per month through LillyDirect’s Self-Pay Pharmacy Solutions and the Zepbound Self-Pay Journey Program.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
PublicationArticleJune 17, 2025Pharmacy TimesJune 2025Volume91 Issue 6Author(s): Dupilumab is FDA-approved for chronic spontaneous urticaria in patients 12+ years, effective as an add-on to antihistamines. Diazepam nasal spray is approved for seizure clusters in individuals 2+ years, with a consistent safety profile across ages. Nampons, designed to stop nosebleeds, are now available at select retailers, using patented microdispersed oxidized cellulose.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
In the ARCADIA long-term extension study, nemolizumab (Nemluvio; Galderma) demonstrated tolerable efficacy and safety outcomes for the treatment of moderate-to-severe atopic dermatitis, with no new safety signals identified compared to results from the ARCADIA 1 (NCT03985943) and ARCADIA 2 (NCT03989349) clinical trials.
-
1 week ago | 
pharmacytimes.com | Kennedy Ferruggia
In the randomized, open-label, multicenter phase 3 NATALEE clinical trial (NCT05306340), ribociclib (Kisqali; Novartis) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease-free survival among individuals with HR-positive (HR+) and HER2-negative (HER2-) early breast cancer.
-
2 weeks ago | 
pharmacytimes.com | Kennedy Ferruggia
Author(s):Fact checked by:The FDA has approved mRNA-1345 (mRESVIA; ModernaTX, Inc), a respiratory syncytial virus (RSV) vaccine, for the prevention of RSV infection among high-risk individuals aged 18 to 59 years.
